{
  "image_filename": "figure_p1_det_0_017.png",
  "image_path": "Hsiao_et_al.__2023_/extracted/figures/figure_p1_det_0_017.png",
  "image_type": "Figure",
  "page_number": 1,
  "block_id": "det_0_017",
  "claim_id": "claim_003",
  "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
  "supports_claim": false,
  "explanation": "The image shows the title of an original article comparing recombinant and standard-dose influenza vaccines in adults under 65, followed by author names and the beginning of the abstract/background section. The visible text notes that trivalent recombinant influenza vaccines contain three times the amount of hemagglutinin protein as standard-dose egg-based vaccines. The image does not present any data or statements about a broader immune response or cross-protection in mismatch seasons, so it does not support the claim. Note: Only the title and the first line of the abstract/background are visible; additional relevant data may be present in other parts of the document not shown.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "The image shows the title of an original article comparing recombinant and standard-dose influenza vaccines in adults under 65, followed by author names and the beginning of the abstract/background section. The visible text notes that trivalent recombinant influenza vaccines contain three times the amount of hemagglutinin protein as standard-dose egg-based vaccines.",
    "evidence_found": null,
    "reasoning": "The image does not present any data or statements about a broader immune response or cross-protection in mismatch seasons, so it does not support the claim.",
    "confidence_notes": "Only the title and the first line of the abstract/background are visible; additional relevant data may be present in other parts of the document not shown."
  }
}